NO329420B1 - Formulering inneholdende testosteron-undekanoat og lakserolje samt anvendelse av disse for fremstilling av medikament for behandling av sykdom - Google Patents
Formulering inneholdende testosteron-undekanoat og lakserolje samt anvendelse av disse for fremstilling av medikament for behandling av sykdom Download PDFInfo
- Publication number
- NO329420B1 NO329420B1 NO20014718A NO20014718A NO329420B1 NO 329420 B1 NO329420 B1 NO 329420B1 NO 20014718 A NO20014718 A NO 20014718A NO 20014718 A NO20014718 A NO 20014718A NO 329420 B1 NO329420 B1 NO 329420B1
- Authority
- NO
- Norway
- Prior art keywords
- castor oil
- liquid carrier
- testosterone undecanoate
- pharmaceutical formulation
- weight
- Prior art date
Links
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 title claims abstract description 31
- 229960000746 testosterone undecanoate Drugs 0.000 title claims abstract description 30
- 239000004359 castor oil Substances 0.000 title claims abstract description 21
- 235000019438 castor oil Nutrition 0.000 title claims abstract description 21
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 238000009472 formulation Methods 0.000 title description 14
- 239000000203 mixture Substances 0.000 title description 14
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 239000004094 surface-active agent Substances 0.000 claims abstract description 11
- 239000003098 androgen Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 229940100688 oral solution Drugs 0.000 claims description 2
- 230000009469 supplementation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 14
- 229960003604 testosterone Drugs 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000002657 hormone replacement therapy Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- -1 propylene glycol Chemical compound 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99302581 | 1999-04-01 | ||
| PCT/EP2000/002677 WO2000059512A1 (en) | 1999-04-01 | 2000-03-27 | Formulation comprising testosteron undecanoate and castor oil |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20014718D0 NO20014718D0 (no) | 2001-09-28 |
| NO20014718L NO20014718L (no) | 2001-09-28 |
| NO329420B1 true NO329420B1 (no) | 2010-10-18 |
Family
ID=8241306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20014718A NO329420B1 (no) | 1999-04-01 | 2001-09-28 | Formulering inneholdende testosteron-undekanoat og lakserolje samt anvendelse av disse for fremstilling av medikament for behandling av sykdom |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1189620B1 (de) |
| JP (1) | JP2002541111A (de) |
| KR (1) | KR100666016B1 (de) |
| CN (1) | CN1155385C (de) |
| AT (1) | ATE269708T1 (de) |
| AU (1) | AU768537B2 (de) |
| BR (1) | BR0009465A (de) |
| CA (1) | CA2366856C (de) |
| CZ (1) | CZ298573B6 (de) |
| DE (1) | DE60011771T2 (de) |
| DK (1) | DK1189620T3 (de) |
| ES (1) | ES2222199T3 (de) |
| HK (1) | HK1043544A1 (de) |
| HU (1) | HU229455B1 (de) |
| ID (1) | ID30481A (de) |
| IL (2) | IL145524A0 (de) |
| MX (1) | MXPA01009919A (de) |
| NO (1) | NO329420B1 (de) |
| NZ (1) | NZ514290A (de) |
| PL (1) | PL195163B1 (de) |
| PT (1) | PT1189620E (de) |
| RU (1) | RU2246296C2 (de) |
| SK (1) | SK286071B6 (de) |
| TR (1) | TR200102769T2 (de) |
| TW (1) | TWI280124B (de) |
| WO (1) | WO2000059512A1 (de) |
| ZA (1) | ZA200107781B (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
| RU2429850C2 (ru) | 2005-04-15 | 2011-09-27 | Кларус Терапьютикс, Инк. | Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| DK2068825T3 (da) | 2006-10-04 | 2011-05-16 | M & P Patent Ag | Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere |
| GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| ES2525520T3 (es) * | 2010-04-12 | 2014-12-26 | Clarus Therapeutics, Inc. | Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas |
| GB201006200D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| RU2599036C2 (ru) * | 2011-01-26 | 2016-10-10 | Аллерган, Инк. | Андрогенная композиция для лечения офтальмологического заболевания |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| BR112016028192A2 (pt) | 2014-06-17 | 2017-08-22 | Merck Sharp & Dohme | gerritdina g. schoonus-gerritsma |
| ES2851332T3 (es) * | 2014-06-19 | 2021-09-06 | Solural Pharma ApS | Forma sólida de dosificación oral de compuestos lipofílicos |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| RU2017111503A (ru) * | 2014-08-29 | 2018-10-05 | Липосин Инк. | КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| EP3544614A4 (de) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | Orale testosteron-undecanoat-therapie |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE9700642D0 (sv) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
-
2000
- 2000-03-27 WO PCT/EP2000/002677 patent/WO2000059512A1/en active IP Right Grant
- 2000-03-27 BR BR0009465-0A patent/BR0009465A/pt not_active Application Discontinuation
- 2000-03-27 DK DK00920588T patent/DK1189620T3/da active
- 2000-03-27 NZ NZ514290A patent/NZ514290A/en not_active IP Right Cessation
- 2000-03-27 SK SK1372-2001A patent/SK286071B6/sk not_active IP Right Cessation
- 2000-03-27 IL IL14552400A patent/IL145524A0/xx active IP Right Grant
- 2000-03-27 EP EP00920588A patent/EP1189620B1/de not_active Expired - Lifetime
- 2000-03-27 TR TR2001/02769T patent/TR200102769T2/xx unknown
- 2000-03-27 DE DE60011771T patent/DE60011771T2/de not_active Expired - Lifetime
- 2000-03-27 PT PT00920588T patent/PT1189620E/pt unknown
- 2000-03-27 CN CNB008059381A patent/CN1155385C/zh not_active Expired - Lifetime
- 2000-03-27 AU AU41111/00A patent/AU768537B2/en not_active Expired
- 2000-03-27 JP JP2000609075A patent/JP2002541111A/ja not_active Withdrawn
- 2000-03-27 RU RU2001129362/15A patent/RU2246296C2/ru active
- 2000-03-27 AT AT00920588T patent/ATE269708T1/de active
- 2000-03-27 CZ CZ20013507A patent/CZ298573B6/cs not_active IP Right Cessation
- 2000-03-27 PL PL00351259A patent/PL195163B1/pl unknown
- 2000-03-27 HU HU0200453A patent/HU229455B1/hu unknown
- 2000-03-27 KR KR1020017012498A patent/KR100666016B1/ko active IP Right Grant
- 2000-03-27 ID IDW00200102082A patent/ID30481A/id unknown
- 2000-03-27 MX MXPA01009919A patent/MXPA01009919A/es active IP Right Grant
- 2000-03-27 ES ES00920588T patent/ES2222199T3/es not_active Expired - Lifetime
- 2000-03-27 CA CA002366856A patent/CA2366856C/en not_active Expired - Lifetime
- 2000-05-11 TW TW089109036A patent/TWI280124B/zh not_active IP Right Cessation
-
2001
- 2001-09-20 IL IL145524A patent/IL145524A/en not_active IP Right Cessation
- 2001-09-20 ZA ZA200107781A patent/ZA200107781B/en unknown
- 2001-09-28 NO NO20014718A patent/NO329420B1/no not_active IP Right Cessation
-
2002
- 2002-07-17 HK HK02105288A patent/HK1043544A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329420B1 (no) | Formulering inneholdende testosteron-undekanoat og lakserolje samt anvendelse av disse for fremstilling av medikament for behandling av sykdom | |
| US11331325B2 (en) | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | |
| EP0904064B1 (de) | Orale pharmazeutische zusammensetzungen mit sexualhormonen | |
| US20050287203A1 (en) | Formulation comprising testosteron undecanoate and castor oil | |
| JP2002541111A5 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP & DOHME BV, NL |
|
| MK1K | Patent expired |